How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

163 results for

Cyclic Lipopeptide

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Daptomycin - Skin and Skin Structure Infections & Bacteremia

Daptomycin - Skin and Skin Structure Infections & Bacteremia Common Drug Review CEDAC Meeting – July 16, 2008; CEDAC Reconsideration – September 17, 2008 Page 1 of 3 Notice of CEDAC Final Recommendation – September 24, 2008 © 2008 CADTH CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION DAPTOMYCIN (Cubicin ® – Oryx Pharmaceuticals Inc.) Description: Daptomycin is a parenteral cyclic lipopeptide antimicrobial agent with bactericidal properties against Gram positive

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

102. Pipeline of Known Chemical Classes of Antibiotics (Full text)

, their spectrum of activity, and the new subclasses under development. The result of the study shows that the new antibiotics in the pipeline belong to the following chemical classes: quinolones, aminoglycosides, macrolides, oxazolidinones, tetracyclines, pleuromutilins, beta-lactams, lipoglycopeptides, polymyxins and cyclic lipopeptides.

2013 Antibiotics PubMed

103. Pharmacokinetics Study of Intraperitoneal Administration of Daptomycin in Peritoneal Infection

of the peritoneal membrane. Based on the recommendations of the International Society for Peritoneal Dialysis, the intraperitoneal route is preferentially recommended. For many antibiotics, pharmacokinetics (intravenous and intraperitoneal) was studied and protocols for IP administration were validated. Daptomycin, is a cyclic lipopeptide natural, active only on Gram-positive bacteria. It is presented as an alternative to vancomycin in infections resistant pathogens. The stability of daptomycin in peritoneal

2013 Clinical Trials

104. Safety and Efficacy Study of Daptomycin When Compared to Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis

problem in the pediatric population, affecting approximately 5/10,000 children each year and accounting for approximately 1% of all pediatric hospitalizations. In children, osteomyelitis arises from bacteremic seeding of the bone metaphysis. Daptomycin, is a cyclic lipopeptide antibacterial active against most clinically significant gram-positive pathogens including drug-resistant strains such as Methicillin Resistant Staphylococcus (S.) aureus (MRSA) and Methicillin Susceptible S. aureus (MSSA

2013 Clinical Trials

105. Biosynthetic Multitasking Facilitates Thalassospiramide Structural Diversity in Marine Bacteria (Full text)

Biosynthetic Multitasking Facilitates Thalassospiramide Structural Diversity in Marine Bacteria Thalassospiramides A and B are immunosuppressant cyclic lipopeptides first reported from the marine α-proteobacterium Thalassospira sp. CNJ-328. We describe here the discovery and characterization of an extended family of 14 new analogues from four Tistrella and Thalassospira isolates. These potent calpain 1 protease inhibitors belong to six structure classes in which the length and composition

2013 Journal of the American Chemical Society PubMed

106. Characterization of two antimicrobial peptides produced by a halotolerant Bacillus subtilis strain SK.DU.4 isolated from a rhizosphere soil sample (Full text)

as a cyclic lipopeptide with a β-hydroxy fatty acid linked to Ser of a peptide with seven α-amino acids (Asp-Tyr-Asn-Gln-Pro-Asn-Ser) and assigned it to iturin-like group of antimicrobial biosurfactants. However, it differed in amino acid composition with other members of the iturin family. Both peptides were active against Gram-positive bacteria, suggesting that they had an additive effect. (...) of chemical extraction and chromatographic techniques. The MALDI-TOF analysis of HPLC purified fractions revealed that the strain SK.DU.4 secreted a bacteriocin-like peptide with molecular mass of 5323.9 Da and a surface-active lipopeptide (m/z 1056 Da). The peptide mass fingerprinting of low-molecular-weight bacteriocin exhibited significant similarity with stretches of secreted lipoprotein of Methylomicrobium album BG8 and displayed 70% sequence coverage. MALDI MS/MS analysis elucidated the lipopeptide

2013 AMB Express PubMed

107. Lyngbyabellins K-N from Two Palmyra Atoll Collections of the Marine Cyanobacterium Moorea bouillonii (Full text)

Lyngbyabellins K-N from Two Palmyra Atoll Collections of the Marine Cyanobacterium Moorea bouillonii Five lipopeptides of the lyngbyabellin structure class, four cyclic (1-3, and 5) and one linear (4), were isolated from the extracts of two collections of filamentous marine cyanobacteria obtained from Palmyra Atoll in the Central Pacific Ocean. Their planar structures and absolute configurations were elucidated by combined spectroscopic and chromatographic analyses as well as chemical synthesis

2012 European journal of organic chemistry PubMed

108. Comparative Evaluation of the Safety & Efficacy of Daptomycin Versus SOC in 2

Bacteremia Drug: Daptomycin Drug: Comparator Phase 4 Detailed Description: S. aureus causes a series of invasive diseases in adults and children, including bacteremia. Infections due to S. aureus in children, particularly those due to methicillin resistant S. aureus (MRSA), are a growing world-wide public health concern. Daptomycin, a cyclic lipopeptide antibacterial agent, shows rapid in vitro bactericidal activity with concentration-dependent killing for Gram-positive organisms, including S. aureus

2012 Clinical Trials

109. Daptomycin-nonsusceptible, vancomycin-intermediate, methicillin-resistant Staphylococcus aureus endocarditis (Full text)

Daptomycin-nonsusceptible, vancomycin-intermediate, methicillin-resistant Staphylococcus aureus endocarditis Due to the emergence of Staphylococcus aureus with reduced vancomycin susceptibility, newer antibiotics, including daptomycin, have been used to treat methicillin-resistant S aureus infections. Daptomycin is a cyclic lipopeptide that is approved to treat S aureus bacteremia and right-sided endocarditis, and reports of S aureus with reduced susceptibility to daptomycin are infrequent

2012 The Canadian Journal of Infectious Diseases & Medical Microbiology PubMed

110. β-lactams increase the antibacterial activity of daptomycin against clinical MRSA strains and prevent selection of DAP-resistant derivatives. (Full text)

β-lactams increase the antibacterial activity of daptomycin against clinical MRSA strains and prevent selection of DAP-resistant derivatives. Methicillin-resistant Staphylococcus aureus (MRSA) has emerged to be one of the most important pathogens both in health care and in community-onset infections. Daptomycin (DAP) is a cyclic anionic lipopeptide recommended for treatment of skin infections, bacteremia, and right-sided endocarditis caused by MRSA. Resistance to DAP (DAP(r)) has been reported

2012 Antimicrobial Agents and Chemotherapy PubMed

111. Occidiofungin's Chemical Stability and In vitro Potency Against Candida species. (Full text)

Occidiofungin's Chemical Stability and In vitro Potency Against Candida species. Occidiofungin is a cyclic glyco-lipopeptide produced by Burkholderia contaminans. MICs against Candida species were between 0.5 and 2.0 μg/ml. Occidiofungin retains its in vitro potency in the presence of 5% and 50% human serum with a minimal lethal concentration (MLC) of 2 and 4 μg/ml, respectively. Time-kill and postantifungal effect (PAFE) experiments of occidiofungin against Candida albicans were performed

2011 Antimicrobial Agents and Chemotherapy PubMed

112. Daptomycin Antibiotic-Lock Therapy in a Rat Model of Staphylococcal Central Venous Catheter Biofilm Infections. (Full text)

Daptomycin Antibiotic-Lock Therapy in a Rat Model of Staphylococcal Central Venous Catheter Biofilm Infections. Antibiotic lock therapy (ALT) is an adjunctive procedure to prevent or treat central venous catheter infections, ensuing catheter-related bacteremia, and catheter-related metastatic infections. Daptomycin is a cyclic lipopeptide that is rapidly bactericidal against methicillin-susceptible and -resistant Staphylococcus aureus. The efficacies of daptomycin against central venous

2011 Antimicrobial Agents and Chemotherapy PubMed

113. Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis. (Full text)

Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis. Daptomycin (DAP) is a cyclic lipopeptide that disrupts the functional integrity of the cell membranes of Gram-positive bacteria in a Ca(2+)-dependent manner. Here we present genetic, genomic, and phenotypic analyses of an evolved DAP-resistant isolate, Dap(R)1, from the model bacterium Bacillus subtilis 168. Dap(R)1 was obtained by serial passages with increasing DAP concentrations, is 30

2011 Antimicrobial Agents and Chemotherapy PubMed

114. Daptomycin

of Washington School of Pharmacy Click here for Patient Education NOTE: This is the Professional Version. CONSUMERS: Daptomycin is a cyclic lipopeptide that has a unique mechanism of action. It binds to the bacterial cell membranes, causing rapid depolarization of the membrane due to potassium efflux and associated disruption of DNA, RNA, and protein synthesis; the result is rapid concentration-dependent bacterial death (see ). Indications Daptomycin has activity against the following: Gram-positive

2013 Merck Manual (19th Edition)

115. Antibacterial (Full text)

in or clinical trials. These drugs however, did not address the entire spectrum of resistance of GNB. According to the WHO fifty one new therapeutic entities (NTEs) - antibiotics (including combinations), are in phase 1-3 clinical trials as of May 2017. Recent entries in the clinical pipeline targeting multidrug-resistant Gram-positive pathogens has improved the treatment options due to marketing approval of new antibiotic classes, the oxazolidinones and cyclic lipopeptides. However, resistance (...) ( , , , and ) have activities. ( , , and ) are usually (with the exception of bactericidal ). Further categorization is based on their target specificity. "Narrow-spectrum" antibiotics target specific types of bacteria, such as or , whereas affect a wide range of bacteria. Following a 40-year break in discovering new classes of antibacterial compounds, four new classes of antibiotics have been brought into clinical use in the late 2000s and early 2010s: cyclic

2012 Wikipedia PubMed

116. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. (Full text)

A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Polymyxins are cationic lipopeptides (five cationic charges) and the last resort for the treatment of serious Gram-negative infections caused by multiresistant strains. NAB741 has a cyclic peptide portion identical to that of polymyxin B but carries in the linear peptide portion a threonyl-D-serinyl residue (no cationic

2010 Antimicrobial Agents and Chemotherapy PubMed

117. Effects of Supported Lipid Monolayer Fluidity on the Adhesion of Hematopoietic Progenitor Cell Lines to Fibronectin-Derived Peptide Ligands for α5β1 and α4β1 Integrins (Full text)

is an important ECM component in many tissues, including the hematopoietic stem cell niche. We examined the adhesion of the M07e and THP-1 hematopoietic progenitor cell lines to fibronectin-derived peptide ligands for the alpha5beta1 (cyclic and linear RGD) and alpha4beta1 (cyclic LDV) integrins as well as the heparin-binding domain (HBD) presented as lipopeptides in fluid and gel SLMs. M07e cells adhered more avidly than THP-1 cells to all of the lipopeptides in fluid and gel surfaces. The adhesion of both (...) cell lines to all peptides was less avid in fluid versus gel SLMs. Adhesion to cyclic LDV (cLDV) and cRGD was similar on gel SLMs for both cell lines. In contrast, adhesion to cLDV was less extensive than to cRGD in fluid SLMs, especially for M07e cells. Adhesion to linear RGD was less avid than to cRGD or cLDV and decreased to a greater extent in fluid SLMs. Human aortic endothelial cells adhered to cRGD in fluid SLMs and remained viable for at least 24 h but did not spread. We also showed

2009 Langmuir : the ACS journal of surfaces and colloids PubMed

118. Anidulafungin During Continuous Venovenous Hemofiltration (CVVHF)

of Vienna Information provided by: Medical University of Vienna Study Details Study Description Go to Brief Summary: The purpose of this trial is to study the pharmacokinetics of anidulafungin during continuous venovenous hemofiltration. Background: Anidulafungin is a cyclic lipopeptide antifungal agent of the echinocandin class. Members of this class of antifungal agents are known to inhibit the synthesis of glucan polymers in fungal cell walls. The spectrum of activity of anidulafungin includes

2009 Clinical Trials

119. Genetic Analysis of Factors Affecting Susceptibility of Bacillus subtilis to Daptomycin. (Full text)

Genetic Analysis of Factors Affecting Susceptibility of Bacillus subtilis to Daptomycin. Daptomycin is the first of a new class of cyclic lipopeptide antibiotics used against multidrug-resistant, gram-positive pathogens. The proposed mechanism of action involves disruption of the functional integrity of the bacterial membrane in a Ca(2+)-dependent manner. We have used transcriptional profiling to demonstrate that treatment of Bacillus subtilis with daptomycin strongly induces the lia operon

2009 Antimicrobial Agents and Chemotherapy PubMed

120. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study. (Full text)

Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study. Daptomycin is a new intravenous cyclic lipopeptide antibiotic, licensed for the treatment of complicated skin and soft tissue infections caused by Gram-positive organisms including both susceptible and resistant strains of Staphylococcus aureus and for the treatment of various infections due to susceptible organisms, including serious and life-threatening Gram

2009 Transplantation PubMed

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>